← All trials
NCT01374581
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2012
- Primary completion
- Jun 1, 2014
- Completion date
- Jun 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 2117
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of AntwerpLead sponsor
- Kazo health centre IV UgandaOverall official - principal investigator
- University of KinshasaOverall official - principal investigator
- Institute of Tropical Medicine, BelgiumCollaborator
- Centre MurazCollaborator
- Makerere UniversityCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- University of KinshasaCollaborator
- Government of BelgiumCollaborator
- University of AntwerpReponsible party - principal investigator
- University of AmsterdamCollaborator
- University of AntwerpStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.